# GPT-5-mini Review

**Role:** External referee review
**Model:** openai/gpt-5-mini
**Paper:** paper.pdf
**Timestamp:** 2026-02-03T19:23:59.822822
**Route:** OpenRouter + LaTeX
**Review mode:** Tri-model (3 independent reviewers)
**Tokens:** 18738 in / 5775 out
**Response SHA256:** 90ae06c3ac807b76

---

Summary
This paper studies whether state expansions of Medicaid postpartum coverage (from 60 days to 12 months) increased Medicaid coverage for women who recently gave birth. It uses ACS PUMS 2017–2019 and 2021–2022, exploits staggered adoption across states, and implements the Callaway & Sant'Anna (2021) staggered DiD estimator plus a suite of robustness checks (Goodman‑Bacon decomposition, Sun‑Abraham style event study, placebo populations/outcomes). The paper’s central empirical conclusion is a small, statistically insignificant ~2.0 percentage point increase in Medicaid coverage among postpartum women in adopting states during the sampled period; the paper argues that this muted effect is plausibly driven by the COVID‑19 PHE continuous enrollment provision (March 2020–May 2023) that rendered the 60‑day cliff non‑binding for much of the adoption window.

Overall assessment: important and timely question; careful use of modern staggered DiD tools; clear institutional framing of the PHE interaction that plausibly explains why cross‑sectional coverage gains are muted in 2021–2022. However, important methodological and substantive limitations remain. The empirical strategy is appropriate for the observed data but the data window (through 2022) overlaps the PHE, so the central causal question of “did the postpartum extension increase coverage when the policy could bite?” remains unanswered. There are also format and presentation problems that should be fixed. Given these issues, the paper is potentially publishable after substantial revisions and additional analyses (see Decision at end).

Below I provide a comprehensive, rigorous review organized according to your requested checklist: format, statistical methodology, identification credibility, literature coverage (with specific missing references and BibTeX), writing quality, constructive suggestions, overall assessment and a required decision.

1. FORMAT CHECK (please fix before resubmission)
- Length: The manuscript (main text + appendices) appears substantial. Based on the LaTeX source, I estimate the compiled paper would be roughly 30–40 pages (main text + figures + appendices). That meets the 25‑page guideline for a top journal, but please report the compiled page count in the submission letter. If you planned a shorter main text, indicate which material is intended for online appendix vs printed article.
- References: The bibliography covers many relevant papers (Callaway & Sant'Anna 2021; Goodman‑Bacon; Sun & Abraham; Rambachan & Roth; Sant'Anna & Zhao). It cites empirical and policy literature on postpartum Medicaid and PHE unwinding. However, several key methodological and inference references are missing (see Section 4 below). Additions required.
- Prose: Major sections (Introduction, Institutional background, Conceptual framework, Data, Empirical strategy, Results, Discussion, Conclusion) are written in paragraph form. No major sections are presented primarily as bullets. PASS here.
- Section depth: Each major section is substantive. However, some sections (e.g., Data, Empirical Strategy) rely heavily on lists for variable definitions. That is acceptable for Data, but ensure the Introduction, Results and Discussion contain at least 3+ substantive paragraphs each (they do, but double‑check in the compiled PDF). PASS but check paragraph structure in final PDF.
- Figures: Figures look well labeled in the source (event‑study, raw trends, adoption map/timeline). Ensure each figure in the compiled PDF has labeled axes, units, readable legend and data points (not just lines). I note the event‑study figures show shaded 95% CIs in the notes; please put exact y‑axis scales, ticks, and sample sizes in figure notes.
- Tables: The placeholders (\input{tables/...}) appear to reference real tables. In the compiled file the tables must show numbers and standard errors (they do in the text). Ensure every coefficient has SEs in parentheses and that all tables include N, sample definition, and estimation weights. PASS if implemented in final PDF.

2. STATISTICAL METHODOLOGY (CRITICAL)
I treat this as the highest priority. A paper cannot pass a top general interest or AEJ: Economic Policy review without correct inference, transparent reporting, and valid identification.

a) Standard errors:
- The manuscript reports standard errors for point estimates (e.g., ATT = 2.0 pp, SE = 1.5 pp) and clusters SEs at the state level (see Robustness Appendix). This is required and present. PASS.

b) Significance testing:
- The paper reports p‑values (e.g., p=0.994 for parallel trends test), and reports which estimates are statistically significant. PASS.

c) Confidence intervals:
- The text reports 95% confidence intervals for key estimates (e.g., 2.0 pp with 95% CI roughly −0.9 to +4.9). The event‑study figures show 95% pointwise CIs. PASS.

d) Sample sizes:
- The paper reports sample sizes (e.g., 169,609 postpartum women, breakdowns by year). Regression tables and individual‑level TWFE tables include N. PASS.

e) DiD with staggered adoption:
- The author uses Callaway & Sant'Anna (2021) to estimate group‑time ATTs and aggregates these. They also present Goodman‑Bacon decomposition and Sun‑Abraham style checks. This addresses the known biases of TWFE in staggered treatment settings. PASS on methodology choice.

However, I have several important technical and inferential concerns that must be addressed before this paper is acceptable:

(i) Limited pre‑treatment horizons and event‑study power: The pre‑period for many treated cohorts is 2017–2019 (two leads shown e = −3 and e = −2). With only two pre‑treatment event times, tests of parallel trends have limited power to detect violations. The paper reports a very high p‑value (0.994) for the pre‑trend test, but that is not a strong guarantee of credible parallel trends in a setting with many confounders and short pre‑periods. Authors should show all cohort‑specific pre‑trends (not only aggregated) and report sensitivity to alternative pre‑trend specifications (e.g., Rambachan & Roth 2023 bounds). See suggestions below.

(ii) Few effective controls and the “near‑universal adoption” problem: The paper correctly notes that eventual adoption is near‑universal, and that in the observed sample there are 22 not‑yet/never treated states serving as controls. While Callaway & Sant'Anna is appropriate, the credibility depends on the not‑yet‑treated states being a valid counterfactual for early adopters. The Goodman‑Bacon decomposition shows ~87% weight on treated vs untreated comparisons. The authors should (a) provide balance tests and pre‑trend plots at the state level for those 22 control states vs treated states; (b) show permutation/randomization inference and leave‑one‑out robustness (especially given potential heterogeneity in unwinding timing); and (c) show sensitivity when excluding Arkansas and Wisconsin (the only true never‑adopters) to see how much control group composition matters.

(iii) Inference with clustered data and small cluster issues: Clustering at the state level is appropriate. However, inference in DiD with staggered adoption and heterogeneous treatment effects can be sensitive to a small number of clusters or to influential clusters. Although you have ~51 clusters, the effective number of clusters used in key comparisons can be smaller because many states are treated. Perform wild cluster bootstrap/two‑way clustering inference or randomization inference on the group‑time ATTs (see Cameron, Gelbach & Miller 2008; Conley & Taber 2011 alternatives). At minimum, report p‑values from a wild cluster bootstrap (wild cluster restricted permutation) and show if significance conclusions change.

(iv) Placebo outcome failure: The employer insurance placebo shows a significant post‑treatment decline (3.2 pp). The paper attributes this to secular labor market forces and the PHE. That is plausible, but it raises concern that the DiD estimates for Medicaid coverage might capture general insurance market shocks correlated with adoption timing. Authors should implement a triple‑difference (postpartum vs non‑postpartum) to difference out common secular shocks to postpartum women, or include more flexible state‑specific time trends and check sensitivity.

(v) Measurement error from annual treatment coding: The ACS PUMS does not include interview month (authors state this), so coding mid‑year effective dates as treated at the state‑year level introduces classical measurement error (some treated observations are really pre‑treatment). That will attenuate estimates. Be explicit about the attenuation bias, and consider alternative coding strategies (sensitivity coding using fraction of year treated if effective date known within state, or sensitivity restricting analysis to states with January 1 effective dates or states with pre/post variation within the ACS by using the 2015–2019 combined PUMS? If no month is present, perhaps use ACS 1‑year microdata for counties? If impossible, quantify expected attenuation with simulation / back‑of‑envelope.)

(vi) PHE confounding: The PHE continuous enrollment provision is central to your interpretation, but it is also endogenous to state behavior (states with larger PHE enrollment gains or different unwinding timing may have chosen different SPA timing). More evidence is needed that the PHE mechanism explains the null/attenuated findings rather than selection. See identification suggestions below.

Conclusion on methodology: The paper uses the correct modern estimators and reports inference. Nevertheless, the authors must (1) strengthen inference via wild cluster bootstrap / permutation tests and show robustness to alternative inference; (2) show cohort‑specific pre‑trends and Rambachan & Roth sensitivity bounds; (3) implement triple‑difference or additional specifications to better account for secular shocks; and (4) explore and mitigate measurement error from annual coding. If these remain unaddressed, the paper is not publishable in a top journal.

3. IDENTIFICATION STRATEGY — credibility, assumptions, robustness, and limitations
- Credibility: The identifying strategy (Callaway & Sant'Anna staggered DiD comparing treated cohorts to not‑yet‑treated states) is appropriate for staggered adoption. The institutional framing (PHE continuous enrollment likely muted the immediate effect) is convincing and carefully explained.
- Key assumptions discussed: The paper discusses the parallel trends assumption and reports a pre‑test from the CS estimator (p = 0.994). However, as noted, the short pre‑period and small number of pre‑treatment years limit the power of this test. The paper also acknowledges potential selection into cohort timing and concurrent policies; that is good. More direct evidence on parallel trends at group level and sensitivity checks are necessary.
- Placebo tests and robustness: The paper includes placebos (high‑income postpartum and non‑postpartum low‑income women) and a placebo outcome (employer insurance). The population placebos are null — a point in favor. But the employer insurance placebo fails (statistically significant change), which undermines confidence that the main DiD isolates the postpartum extension effect rather than other contemporaneous forces. I recommend adding a triple‑difference (treated postpartum vs treated non‑postpartum vs control postpartum vs control non‑postpartum) to remove common shocks affecting new mothers and women generally, and showing results with and without state‑specific linear or quadratic trends. Also, explore heterogeneous results by state unwinding intensity/timing (some states began redeterminations earlier than others) — you can exploit variation in unwinding timing to test the PHE mechanism.
- Do conclusions follow evidence? The cautious interpretation (muted measured effects during PHE, true bite expected post‑PHE) is reasonable. But the claim that "we cannot say the extension increased coverage" should be tempered: the paper is unable to detect effects in the PHE period, and inferences about the post‑PHE world remain speculative until new data are analyzed. The authors should tone down strong claims about welfare until post‑PHE data or administrative data analysis confirm.

4. LITERATURE — missing references and why to include them
The paper cites many important works, but several methodological and inference papers relevant to staggered DiD/event‑study inference and robust inference are missing. Below I list recommended additions with short justifications and BibTeX entries you should include.

a) Borusyak, Jaravel, and Spiess — event‑study / staggered adoption critique and solutions
- Why relevant: Their “revisiting event study” paper provides alternative estimators and diagnostics for event studies with staggered treatment timing and heterogeneous effects; it complements Callaway & Sant'Anna and Sun & Abraham approaches.
BibTeX:
@article{borusyak2022revisiting,
  author = {Borusyak, Kirill and Jaravel, Xavier and Spiess, J{\"o}rg},
  title = {Revisiting Event Study Designs},
  journal = {arXiv preprint arXiv:2102.05003},
  year = {2022}
}
(If you prefer a published version, cite the 2022/2021 versions appropriate. Use the DOI/accepted version if available.)

b) Rambachan & Roth (already cited) — you cite them; please implement their sensitivity approach explicitly to show robustness to potential pre‑trend violations.
BibTeX already present in manuscript; ensure you reference the correct journal entry.

c) Cameron, Gelbach & Miller — wild cluster bootstrap
- Why relevant: Important methodology for conducting inference with few clusters or clustered DiD; reporting wild cluster bootstrap p‑values is a standard demand in applied microeconometrics for policy evaluation papers.
BibTeX:
@article{cameron2008bootstrap,
  author = {Cameron, A. Colin and Gelbach, Jonah B. and Miller, Douglas L.},
  title = {Bootstrap-Based Improvements for Inference with Clustered Errors},
  journal = {Review of Economics and Statistics},
  year = {2008},
  volume = {90},
  pages = {414--427}
}

d) Conley & Taber 2011 — inference with few treated clusters / permutation inference
- Why relevant: Offers guidance on inference when treatments occur in a small number of clusters; relevant given near‑universal adoption and small effective control pool.
BibTeX:
@article{conley2011inference,
  author = {Conley, Timothy G. and Taber, Christopher R.},
  title = {Inference with ``Difference in Differences'' with a Small Number of Policy Changes},
  journal = {Review of Economics and Statistics},
  year = {2011},
  volume = {93},
  pages = {113--125}
}

e) Borusyak & Jaravel (2021) — alternative estimator for staggered treatments (imputation)
- Why relevant: They propose an imputation approach useful for staggered designs; could be a robustness check and comparison to CS estimator.
BibTeX:
@article{borusyak2021cred,
  author = {Borusyak, Kirill and Jaravel, Xavier},
  title = {Credible causal inference for panel data with staggered treatment timing},
  journal = {arXiv preprint arXiv:2007.14001},
  year = {2021}
}

f) De Chaisemartin & D'Haultfœuille (2020) — already cited. Good.

g) Additional applied literature on postpartum Medicaid extensions and PHE unwinding:
- Include state‑level administrative analyses and KFF reports with explicit measures of unwinding timing and redetermination intensity (you cite KFF 2024; add more detailed state unwinding studies if available).

5. WRITING QUALITY (CRITICAL)
- Prose vs. bullets: Major sections are in paragraph form, not bullets. PASS.
- Narrative flow: The paper tells a compelling institutional story (postpartum cliff → ARPA SPA → near‑universal adoption → PHE overlap → attenuated measured effect). The Introduction hooks with maternal mortality statistics (good). The flow from motivation → identification → results → interpretation is logical. PASS.
- Sentence quality: Mostly crisp and readable; however, some paragraphs are long and could be tightened for a top journal. Move some methodological detail to an online appendix; keep the main story crisp.
- Accessibility: Overall accessible to non‑specialists. However, some econometric terms (e.g., “forbidden comparisons”, “CS aggregation”) need brief, reader‑friendly explanations on first use. Include short intuition for the Callaway & Sant'Anna estimator (two sentences).
- Figures/Tables: Ensure titles, axis labels, units, and notes are sufficiently detailed and that figures are legible at typical journal sizes. Each figure/table should be understandable standalone. Add sample sizes in figure notes, and indicate which sample is used (weighted/unweighted). Fix the event‑study y‑axis scales to be comparable across panels or explicitly justify differences.

Major writing fixes to make the paper "publishable" at a top journal:
- Shorten the Introduction to focus on the empirical question and main findings (one page), then orient readers to institutional details and PHE interaction succinctly.
- Move some technical details (e.g., full variable lists, data retrieval code comments, extra decomposition tables) to online appendix.
- Tighten sentences; avoid repeated claims about the PHE confound — present once and illustrate with robust checks.

6. CONSTRUCTIVE SUGGESTIONS (to make the paper substantially more impactful)
The paper already contains many robustness checks. To improve credibility and impact, implement the following as feasible:

A. Primary empirical improvements (highest priority)
1) Use post‑PHE data: The clearest fix is to re‑estimate using 2023 and (if available) 2024 ACS PUMS or state administrative Medicaid enrollment data. The paper's institutional argument hinges on the PHE ending in May 2023; without post‑PHE data the central causal question remains unanswered. If 2023 PUMS is now available, incorporate it.

2) Administrative Medicaid enrollment data: State Medicaid administrative data (monthly enrollment) would be far better for identifying the discontinuity at 60 days and detecting the extension’s bite post‑PHE. Administrative data allow exact timing (month) and direct observation of disenrollment. If feasible, analyze one or more states’ Medicaid enrollment files (especially a pair with different adoption timing) as a complementary exercise.

3) Triple‑difference: Add a triple‑difference design (postpartum vs non‑postpartum × treated vs control × before vs after), which helps remove shocks common to women of similar age and income, addressing the employer‐insurance placebo failure.

4) Wild cluster bootstrap and permutation inference: Report wild cluster bootstrap p‑values and, where appropriate, Conley‑Taber style permutation p‑values for the CS aggregated ATTs to confirm inference robustness.

5) Rambachan & Roth sensitivity: Implement the Rambachan & Roth (2023) sensitivity analysis for the event‑study pre‑trend assumption and report bounds on treatment effects allowing for plausible deviations from parallel trends.

B. Additional robustness and heterogeneity
6) Unwinding timing heterogeneity: Use state variation in unwinding start date and intensity (KFF collects unwinding timing; some states paused redeterminations longer) to test the PHE mechanism: effects should be stronger where unwinding was more aggressive and where adoption predated unwinding.

7) Cohort‑specific event studies: Present cohort‑specific event studies (e.g., comparing 2021 adopters to their not‑yet controls vs 2022 adopters) to check heterogeneity in dynamics and to see if early adopters differ.

8) Alternative estimators: Implement Borusyak & Jaravel (imputation) or Borusyak/Jaravel/Spiess event‑study adjustments as robustness checks and compare estimates.

9) Measurement error correction: Quantify attenuation bias induced by coding mid‑year effective dates as full‑year treatment (simulate using assumed uniform interview timing or state effective month). If possible, for states with April 1 effective dates, restrict sample to respondents whose survey interview month is likely after April (this may not be possible in PUMS; if unavailable, state the limitation explicitly and quantify attenuation via simulation).

10) Expand placebo/heterogeneity: Show results by race/ethnicity, parity (first birth vs higher order), and by state Medicaid expansion status (you have this but consider more granular heterogeneity by baseline postpartum uninsured rates).

C. Presentation and interpretation
11) Tone down causal claims limited by data: Reframe conclusions to emphasize “no detectable effect during PHE period” rather than “policy did not increase coverage.” Be explicit about what the design identifies (ATT in 2021–2022 period) and what remains unknown (post‑PHE effects).

12) Add a clear table that maps adoption date, effective date, adoption mechanism (SPA vs 1115 waiver), and whether effective date is before/after PHE end — to help the reader see direct overlap.

13) Provide code/data availability statement and reproducibility files (you have a GitHub URL; make sure data generation code and key scripts are included in replication package or clarify restricted data restrictions).

7. OVERALL ASSESSMENT
- Key strengths:
  - Timely and policy‑relevant question with direct implications for maternal care policy.
  - Appropriate use of modern staggered DiD tools (Callaway & Sant'Anna), plus diagnostic exercises (Goodman‑Bacon decomposition, Sun‑Abraham).
  - Thoughtful and plausible institutional story about PHE continuous enrollment muting measured effects—this is the paper’s main conceptual contribution.
  - Large sample size from ACS PUMS; clear sample construction and many relevant robustness checks.

- Critical weaknesses:
  - The main empirical period (through 2022) overlaps with the PHE, so the design cannot credibly estimate the policy’s effect when the policy could actually “bite.” This is the most important limitation; further data (post‑PHE / administrative) are required to answer the substantive question posed in the title.
  - Placebo outcome (employer insurance) shows significant change post‑treatment — raises concerns about confounding secular forces correlated with adoption timing; stronger identification (triple‑diff, cohort‑specific checks) is needed.
  - Inference needs additional robustness (wild cluster bootstrap, permutation tests), and sensitivity to pre‑trend violations should be explicitly quantified with Rambachan & Roth bounds.
  - Some methodological literature and inference references are missing and should be added.

- Specific suggestions for improvement (summarized):
  1. Re‑run analysis including 2023 (and 2024 if available) ACS PUMS, or—preferably—state Medicaid administrative enrollment data to capture post‑PHE dynamics.
  2. Add a triple‑difference specification and cohort‑specific event studies.
  3. Provide wild cluster bootstrap / permutation inference p‑values and Rambachan & Roth sensitivity bounds.
  4. Present cohort‑specific pre‑trends and state‑level balance checks for treated vs not‑yet‑treated states; consider excluding Arkansas/Wisconsin in sensitivity checks.
  5. Add missing methodological citations (Borusyak & Jaravel; Cameron, Gelbach & Miller; Conley & Taber) and discuss their implications for inference.
  6. Tighten prose and move technical details to an online appendix; make figures/tables self‑contained.

DECISION: MAJOR REVISION

Rationale for decision: The paper addresses an important policy question and uses appropriate modern methods, but the core empirical window largely coincides with the COVID‑19 PHE that the authors argue masks the policy effect. Without post‑PHE data or administrative enrollment analysis, the paper cannot answer the central causal question. In addition, inference and sensitivity checks (wild cluster bootstrap/permutation inference, Rambachan & Roth bounds, triple‑difference) are needed to increase credibility given secular shocks and the employer‑insurance placebo failure. If the authors implement the suggested analyses (especially including 2023+ data or administrative enrollment data and stronger inference), strengthen robustness and sensitivity analyses, and tighten presentation, the paper could be suitable for a top general interest or policy journal.